002099.SZ
海翔药业
SZSE · Healthcare · C 制造业 · CN
CNY 5.05
−3.63%Year over year
Reported trailing growth
- Revenue
- -1.9%
- EBITDA
- —
- EBIT
- +79.8%
- EPS
- +79.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -11.7%
- EBITDA
- -16.4%
- EBIT
- +76.2%
- Net income
- +72.4%
- EPS
- +71.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026